Logo
Login
$PROK
$1.36 -$0.05 (3.55%) Close

Company Executives

$PROK Management Team

Mr. Ethan Holdaway

Investor Relations

Age -
Compensation -
Sex Male

Mr. Pablo Legorreta

Chairman of the Board

Age 61
Compensation $264.4K USD
Sex Male

Dr. Bruce Culleton

Chief Executive Officer

Director

Age 57
Compensation $1.016M USD
Sex Male

Mr. James Coulston

Chief Financial Officer

Age 49
Compensation $2.287M USD
Sex Male

Dr. Darin Weber

Chief Regulatory Officer

Senior Vice President- Global Regulatory

Quality Management & Commercial

Age 56
Compensation -
Sex Male

Mr. Todd Girolamo

Chief Legal Officer

Age 59
Compensation $1.261M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 17, 2026
Directors
8
serving now
Independent
1 of 3
stated in the proxy; 5 not stated
Average tenure
3.9 years
from year joined
CEO also chairs the board
No
Pablo Legorreta
Director Age On board Independent Committees Other public boards 2025 pay Source
William F. Doyle
Lead independent director
 Not stated 2022
4 years
 Independent None stated Elanco Animal Health, Inc. $129,883
Alan M. Lotvin, M.D.
Not stated 2022
4 years
 Not stated None stated None stated $143,383
Brian J. G. Pereira, M.D.
Not stated 2022
4 years
 Not stated None stated None stated $139,383
Jennifer Fox
Not stated 2022
4 years
 Not stated None stated Apogee Therapeutics, Inc. $132,383
José Ignacio Jiménez Santos
Not stated 2022
4 years
 Not stated None stated None stated $117,383
Bruce Culleton, M.D.
CEO
 Not stated 2023
3 years
 Not independent None stated None stated Paid as CEO
Pablo Legorreta
Board chair
 Not stated Not stated Not independent None stated Royalty Pharma plc $144,633
Uma Sinha, Ph.D.
Not stated 2022
4 years
 Not stated None stated None stated $124,883

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 17, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans